<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02912156</url>
  </required_header>
  <id_info>
    <org_study_id>YSP-RIH3001-01</org_study_id>
    <nct_id>NCT02912156</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Two Different Formulation of Voriconazole</brief_title>
  <official_title>A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Formulation of Voriconazole 200mg Tablets in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yung Shin Pharm. Ind. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yung Shin Pharm. Ind. Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different
      Formulation of Voriconazole 200 mg Tablets in Healthy Adult Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration (AUC)</measure>
    <time_frame>Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Drug Concentration (Cmax)</measure>
    <time_frame>Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (T1/2)</measure>
    <time_frame>Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the (first) moment plasma concentration-time curve (AUMC)</measure>
    <time_frame>Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Within 8 weeks prior to the study, subjects were screened for their eligibility.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Fungus Infection</condition>
  <arm_group>
    <arm_group_label>Vaway FC Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaway FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VFEND FC Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VFEND FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaway FC Tablets 200mg (Voriconazole)</intervention_name>
    <arm_group_label>Vaway FC Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VFEND FC Tablets 200mg (Voriconazole)</intervention_name>
    <arm_group_label>VFEND FC Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult, aged between 20 to 45 years old.

          2. Physically and mentally healthy subjects as confirmed by an interview, medical history
             review, clinical examination, laboratory tests, chest x-ray and electrocardiogram
             (ECG).

               -  No clinically significant finding in clinical examination and laboratory tests
                  within two months (60 days) prior to administration of study medication;

               -  Normal or clinically not significant at the discretion of the investigator chest
                  X-ray and ECG results within six months (180 days) prior to administration of
                  study medication.

          3. Body weight was above 50 kg for male and 45 kg for female.

          4. The body mass index should be between 18 and 27; body mass index equals [weight
             (kg)]/[height (m)]2.

          5. Laboratory determinations results were within normal range or considered not
             clinically significant by the investigator, including: Serum Glutamic Oxaloacetic
             Transaminase (SGOT, same as AST), Serum Glutamic Pyruvic Transaminase (SGPT, same as
             ALT), albumin, glucose, creatinine, uric acid, cholesterol, Triglycerides (TG),
             Gamma-Glutamyl-Transpeptidase (Î³-GT), alkaline phosphatase, total bilirubin, Blood
             Urea Nitrogen(BUN),Hepatitis B surface antigen (HBsAg), Anti-Hepatitis C virus
             (Anti-HCV) and Anti-Human Immunodeficiency Virus (Anti-HIV) test.

          6. Hematology test results were within normal range or considered not clinically
             significant by the investigator, including: hemoglobin, hematocrit, White Blood Cell
             (WBC) count, Red Blood Cell (RBC) count, platelet count and WBC count with
             differential.

          7. Urinalysis results were within normal range or considered not clinically significant
             by the investigator, including: glucose, protein, RBC, WBC, epith, casts and bacteria.

          8. Adequate contraceptive methods must be used during two weeks prior and two weeks after
             to the administration of study medication.

          9. Female subject who was:

               -  Using adequate contraception since last menstruation and no plan for conception
                  during the study.

               -  Non-lactating.

               -  Had negative pregnancy test (urine) prior to the study.

         10. Informed consent form signed.

        Exclusion Criteria:

          1. A history of drug or alcohol abuse within 24 weeks prior to the study.

          2. History of drug allergy, allergic constitution, asthma or retinal disease.

          3. Myopia worse than 6.0 diopters.

          4. A clinically significant illness (such as hematological malignancy) within the past 4
             weeks

          5. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic,
             neurological, pulmonary or gastrointestinal disease within the past 4 weeks.

          6. Planned vaccination during the study.

          7. Participation of any clinical investigation during the last 60 days.

          8. Regular use of any medication during the last 4 weeks.

          9. Single use of any medication during the last 2 weeks.

         10. Blood donation of more than 250 mL within the past 12 weeks.

         11. Individuals were judged by the investigator to be undesirable as subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

